Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algeron vs Pegasys in Chronic Hepatitis C
NCT01889433Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Jul 2013
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of ropeginterferon alfa-2b in hepatitis C (HCV) (2 arms), sponsored by BIOCAD. Primary endpoint: Early Virologic Response at 12 weeks. Started Jul 2013; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01889433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889433.